Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

MLA

Hexner, Elizabeth O., et al. “Phase I Dose Escalation Study of Lestaurtinib in Patients with Myelofibrosis.” Leukemia & Lymphoma, vol. 56, no. 9, Sept. 2015, pp. 2543–51. EBSCOhost, https://doi.org/10.3109/10428194.2014.1001986.

APA

Hexner, E. O., Mascarenhas, J., Prchal, J., Roboz, G. J., Baer, M. R., Ritchie, E. K., Leibowitz, D., Demakos, E. P., Miller, C., Siuty, J., Kleczko, J., Price, L., Jeschke, G., Weinberg, R., Basu, T., Pahl, H. L., Orazi, A., Najfeld, V., Marchioli, R., & Goldberg, J. D. (2015). Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leukemia & Lymphoma, 56(9), 2543–2551. https://doi.org/10.3109/10428194.2014.1001986

Chicago

Hexner, Elizabeth O., John Mascarenhas, Josef Prchal, Gail J. Roboz, Maria R. Baer, Ellen K. Ritchie, David Leibowitz, et al. 2015. “Phase I Dose Escalation Study of Lestaurtinib in Patients with Myelofibrosis.” Leukemia & Lymphoma 56 (9): 2543–51. doi:10.3109/10428194.2014.1001986.